Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (Nexus)
This study is currently recruiting participants.
Verified March 2014
by Lpath, Inc.
Study NCT01414153 Information provided by Lpath, Inc.
First Received on August 9, 2011. Last Updated on March 18, 2014
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Wet Macular Degeneration
More general conditions related to this trial
Interventions listed in this trial
4.0 mg iSONEP
0.5 mg iSONEP
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Angiogenesis Modulating Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers